Home  »  Markets   »  Why should you keep an eye on Moderna Inc. (MRNA)?...

Why should you keep an eye on Moderna Inc. (MRNA)?

Moderna Inc. (NASDAQ: MRNA) is 7.99% higher on its value in year-to-date trading and has touched a low of $115.03 and a high of $217.25 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MRNA stock was last observed hovering at around $190.38 in the last trading session, with the day’s gains setting it 3.6% off its average median price target of $213.50 for the next 12 months. It is also 61.66% off the consensus price target high of $506.00 offered by 20 analysts, but current levels are -74.76% lower than the price target low of $111.00 for the same period.

Currently trading at $193.98, the stock is 3.12% and 5.89% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.04 million and changing 1.89% at the moment leaves the stock 25.45% off its SMA200. MRNA registered 11.44% gain for a year compared to 6-month gain of 14.86%.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

The stock witnessed a 2.15% loss in the last 1 month and extending the period to 3 months gives it a 57.04%, and is 3.15% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.17% over the week and 5.16% over the month.

Moderna Inc. (MRNA) has around 2700 employees, a market worth around $73.14B and $21.39B in sales. Current P/E ratio is 7.01 and Fwd P/E is 55.11. Profit margin for the company is 55.00%. Distance from 52-week low is 68.63% and -10.71% from its 52-week high. The company has generated returns on investments over the last 12 months (81.90%).

Moderna Inc. (MRNA) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Moderna Inc. (MRNA) is a “Overweight”. 20 analysts offering their recommendations for the stock have an average rating of 2.40, where 9 rate it as a Hold and 3 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Moderna Inc. is expected to release its quarterly report on 05/11/2023.The EPS is expected to shrink by -24.70% this year.

Moderna Inc. (MRNA) Top Institutional Holders

The shares outstanding are 390.00M, and float is at 346.94M with Short Float at 4.05%.

Moderna Inc. (MRNA) Insider Activity

A total of 376 insider transactions have happened at Moderna Inc. (MRNA) in the last six months, with sales accounting for 297 and purchases happening 79 times. The most recent transaction is an insider sale by Bancel Stephane,the company’sChief Executive Officer. SEC filings show that Bancel Stephane sold 40,000 shares of the company’s common stock on Jan 19 at a price of $192.06 per share for a total of $7.68 million. Following the sale, the insider now owns 5.41 million shares.

Moderna Inc. disclosed in a document filed with the SEC on Jan 18 that Bancel Stephane (Chief Executive Officer) sold a total of 40,000 shares of the company’s common stock. The trade occurred on Jan 18 and was made at $197.96 per share for $7.92 million. Following the transaction, the insider now directly holds 5.41 million shares of the MRNA stock.

Still, SEC filings show that on Jan 18, AFEYAN NOUBAR (Director) disposed off 10,000 shares at an average price of $200.20 for $2.0 million. The insider now directly holds 2,247,209 shares of Moderna Inc. (MRNA).

Moderna Inc. (MRNA): Who are the competitors?

The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 1.30% up over the past 12 months and Pfizer Inc. (PFE) that is -15.75% lower over the same period.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts